A study done in 2015 by PharmaExec sought to estab
Post# of 153887
(Total Views: 757)
Posted On: 10/15/2021 2:47:50 PM
A study done in 2015 by PharmaExec sought to establish the value of a BTD. To begin, the inherent beneficial value is 2.5 years earlier approval for a New Molecular Entity (EME) and 3.5 years earlier approval for drugs under Orphan Status or accelerated approval designations. Since the program began in 2012...a total of 130 FDA approvals are split between 19 public companies and 5 private companies.
The average MKT CAP is $138.2 Billion.
The weighted average is $174.1 Billion...obviously suggesting Big Pharma players have the greatest number of BTD's.
The smaller subset of companies... that has only ONE approval totals 17.
The average Valuation of these companies is $8.23 Billion. Some private (4) companies got a BTD on very obscure indications...so a value of $8.0 Billion for a BTD could be reasonable.
A point of interest...ABBVie is # 5 on the list with 11 BTD's and Gilead has 4 BTD's.
The companies acquired After BTD total 12.
ALL the companies with 2 or more BTD's were swallowed up by Big Pharma.
ANY company with 2 or more BTD's would be in the HOT zone for acquisition.
*Market Size is the Determinant in BTD Valuation*
Acadia Pharmaceuticals for example has a Market Cap of $2.86 Billion and trades at $17.80 as of this morning. On the second BTD, it was averaging $50.00 Plus starting in late December 2019 and slid to $17-$18. in early September of this year. The patient population for their drug is 2.4 million...with only half currently being treated.
The slide in PPS is a result of the FDA finding deficiencies... in the application for its psychosis drug Nuplazid, which Acadia is addressing.
"Leronlimab is a PLATFORM technology drug and they could see a minimum of 2-4 BTD's in the coming year. Conservative revenues range from $2.1 Billion to $4.2 Billion exceeding all measures of blockbuster status". "This is clearly one to watch."__Theodore Zucconi, PhD in Chemistry, Masters Certificate in International Finance and Program/Project Management.
38 years in High Tech and Biotech... I wonder Why... he's Long?
The average MKT CAP is $138.2 Billion.
The weighted average is $174.1 Billion...obviously suggesting Big Pharma players have the greatest number of BTD's.
The smaller subset of companies... that has only ONE approval totals 17.
The average Valuation of these companies is $8.23 Billion. Some private (4) companies got a BTD on very obscure indications...so a value of $8.0 Billion for a BTD could be reasonable.
A point of interest...ABBVie is # 5 on the list with 11 BTD's and Gilead has 4 BTD's.
The companies acquired After BTD total 12.
ALL the companies with 2 or more BTD's were swallowed up by Big Pharma.
ANY company with 2 or more BTD's would be in the HOT zone for acquisition.
*Market Size is the Determinant in BTD Valuation*
Acadia Pharmaceuticals for example has a Market Cap of $2.86 Billion and trades at $17.80 as of this morning. On the second BTD, it was averaging $50.00 Plus starting in late December 2019 and slid to $17-$18. in early September of this year. The patient population for their drug is 2.4 million...with only half currently being treated.
The slide in PPS is a result of the FDA finding deficiencies... in the application for its psychosis drug Nuplazid, which Acadia is addressing.
"Leronlimab is a PLATFORM technology drug and they could see a minimum of 2-4 BTD's in the coming year. Conservative revenues range from $2.1 Billion to $4.2 Billion exceeding all measures of blockbuster status". "This is clearly one to watch."__Theodore Zucconi, PhD in Chemistry, Masters Certificate in International Finance and Program/Project Management.
38 years in High Tech and Biotech... I wonder Why... he's Long?
(19)
(0)